Summary
This editorial explores the current landscape of pulmonary reperfusion strategies in patients with high-risk pulmonary embolism (PE). It underscores the centrality of rapid hemodynamic stabilization and reperfusion in managing high-risk PE and analyzes recent data from a large target trial emulation by Stadlbauer et al. The authors conclude that while systemic thrombolysis (SYS) remains the standard, catheter-directed therapies (PCDT) and surgical thrombectomy (ST) appear equally effective, with lower bleeding risk observed in PCDT. The findings support timely reperfusion as essential, while VA-ECMO should be used as a bridge—not a standalone therapy.
Key Points:
- Core Treatment Objectives in High-Risk PE Rapid restoration of pulmonary perfusion and hemodynamic stabilization is critical; systemic thrombolysis remains first-line per current guidelines, but alternative reperfusion strategies are emerging.
- Limitations of VA-ECMO Alone Data suggest VA-ECMO with anticoagulation alone is associated with up to 34% higher in-hospital mortality compared to SYS, ST, or PCDT, highlighting its inadequacy as a standalone therapy.
- Target Trial Emulation Approach Stadlbauer et al. used a rigorous emulated target trial methodology across 34 European centers to compare reperfusion strategies in a real-world, observational dataset, offering high-quality evidence.
- Comparable Efficacy Among Reperfusion Strategies No statistically significant difference in mortality was found between systemic thrombolysis, surgical thrombectomy, and percutaneous catheter-directed therapy, suggesting all are valid reperfusion options.
- Major Bleeding Risk Differences PCDT had the lowest risk of major bleeding (15.0%) compared to ST and SYS, while VA-ECMO had the highest bleeding risk (47.6%), underscoring the potential safety advantage of catheter-based approaches.
- Use of VA-ECMO as a Bridge VA-ECMO should be considered as a bridge to reperfusion (e.g., SYS or PCDT) in patients with cardiac arrest or refractory circulatory collapse—not as a definitive treatment.
- Guideline Ambiguity on Alternatives to Thrombolysis Current ESC guidelines do not recommend PCDT or ST as first-line treatments due to insufficient high-level evidence, but reserve them for thrombolysis contraindications or failure.
- Potential for PCDT as Preferred Strategy Given its non-inferior survival and favorable safety profile, PCDT could be considered for future trials as a potential first-line reperfusion approach in high-risk PE patients.
- Right Ventricular Unloading is Key Partial thrombus removal—not necessarily full clot resolution—is sufficient to improve hemodynamics and unload the RV, making less invasive strategies like PCDT biologically rational.
- Implications for Future Research The findings justify future randomized controlled trials comparing SYS versus PCDT as primary strategies, especially for patients with high bleeding risk or contraindications to thrombolytics.
Conclusion
In patients with high-risk PE, timely pulmonary reperfusion is critical for survival. Systemic thrombolysis remains first-line, but surgical and catheter-based approaches offer equivalent efficacy. VA-ECMO should not be used alone but rather as a bridge to reperfusion. The emerging data favor PCDT as a potentially safer, effective alternative that merits testing in randomized trials.
Watch the following video on “The management of pulmonary embolism”
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
